Preventive effects of D-004, a lipid extract from Cuban royal palm (Roystonea regia) fruits, on testosterone-induced prostate hyperplasia in intact and castrated rodents

Drugs under Experimental and Clinical Research

Volumn 30, Issue 5-6, 2004, Pages 227-233

  Arruzazabala, M L ^a   Carbajal, D ^a   Mas R ^a   Molina, V ^a   Rodriguez E ^a   Gonzalez V ^a   Ferreiro, Rosa Más ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

D 004; PLANT EXTRACT; ROYSTONEA REGIA EXTRACT; TESTOSTERONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARECACEAE; ARTICLE; CASTRATION; CONTROLLED STUDY; CUBA; DOSE RESPONSE; FRUIT; MALE; NONHUMAN; PROSTATE HYPERTROPHY; RAT; SABAL; STATISTICAL ANALYSIS;

ANIMALS; ARECACEAE; CASTRATION; CUBA; FRUIT; LIPIDS; MALE; MICE; PLANT EXTRACTS; PROSTATIC HYPERPLASIA; RATS; RATS, SPRAGUE-DAWLEY; TESTOSTERONE;

EID: 11444251418     PISSN: 03786501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Clinton J.J. Benign prostatic hyperplasia (BPH)-diagnosis and treatment. J.A.M.A., 271, 1151, 1994.
2. McCarthy M. BPH guidelines. Lancet, 343, 473, 1994.
3. Oesterling J.E. Benign prostatic hyperplasia: Medical and minimal invasive treatment options. N. Eng. J. Med., 332, 99, 1995.
4. Barry M.J., Rochrborn C.G. Benign prostatic hyperplasia. Br. Med. J., 323, 1042, 2001.
5. Carson C., Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology, 61(Suppl. 1), 2, 2003.
6. Bartsch G., Rittmaster R.S., Klocker H. Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia. Urologe A, 41, 412, 2002.
7. Boyle P., Gould A.L., Roehrborn C.G. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials. Urology, 48, 398, 1996.
8. Andro M.-C., Riffaud J.-P. Pygeum africanum extract for the treatment of patients with benign prostatic hyperplasia: A review of 25 years of published experience. Curr. Ther. Res., 56, 796, 1995.
9. Rhodes L., Primka R.L., Berman C., et al. Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts on in vitro and in vivo 5 alpha reductase inhibition. Prostate, 22, 43, 1993.
10. Bombardelli E., Morazzoni P. Serenoa repens (Bartram) JK Small. Fitoterapia, 48, 99, 1997.
11. Plosker G.L., Brodgen R.N. Serenoa repens (Permixon): A review of its pharmacological and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging, 9, 379, 1996.
12. Wilt T.J., Ishani A., Stark G., et al. Saw palmetto extracts for treatment of benign prostatic hyperplasia: A systematic review. JAMA, 280, 1604, 1998.
13. Gordon A.E., Shaughnessy A.F. Saw palmetto for prostate disorders. Am. Fam. Physician, 67, 1281, 2003.
14. Goepel M., Hecker U., Krege S., et al. Saw palmetto extracts potently and non-competitively inhibit human alpha 1 adrenoceptors in vitro. Prostate, 38, 208, 1999.
15. Marks E. Effects of saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J. Urol., 163, 1451, 2000.
16. Carraro J.C., Raynaud J.P., Koch G., et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate, 29, 231, 1996.
17. Paubert-Braquet M., Mencia Huerta J.M., Cousse H., Braquet P. Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon) on the ionophore A23187-stimu/ated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot. Essent. Fatty Acids, 57, 299, 1997.
18. Paubert-Braquet M., Richardson F.O., Servent-Saez N., et al. Effect of Serenoa repens extract (Permixon) on estradiol/testosterone-induced experimental prostate enlargement in the rat. Pharmacol. Res., 34, 171, 1996.
19. Chaudry A.A., Wahle K.W., McClinton S., Moffat L.E. Arachidonic acid metabolism in benign and malignant prostate tissue in vitro: Effects of fatty acids and cyclooxygenase inhibitors. Int. J. Cancer, 57, 176, 1994.
20. Carbin B.E., Larsson B., Lindahl O. Treatment of benign prostatic hyperplasia with phytosterols. Br. J. Urol., 66, 639, 1990.
21. Zona S. Notes on Roystonea in Cuba. Principes, 35, 225, 1991.
22. Laguna A., Rodríguez E., et al. (Laboratorios Dalmer, S.A) 2003. Pharmaceutical composition and procedure for the prevention and treatment of prostate hyperplasia and prostatitis obtained from the fruits of Roystonea regia (Cuban royal palm). (CUB PAT/2003)
23. Pandita R.K., Persson K., Hedlund P., Andersson K.E. Testosterone-induced prostatic growth in the rat causes bladder overactivity unrelated to detrusor hypertrophy. Prostate, 35, 102, 1998.
24. Scolnik M.D., Servadio C., Abramovici A. Comparative study of experimentally induced benign and atypical hyperplasia in the ventral prostate of different rat strains. J. Androl., 15, 287, 1994.
25. Wright A., Lynn N, Thomas R.C., et al. Relative potency of testosterone and dihydrotestosterone in preventing atrophy and apoptosis in the prostate of the castrated rat. J. Clin. Invest., 98, 2558, 1996.